






The article contrasts CrowdStrike’s FY2026 revenue of $4.8B (+21.7% YoY) but net loss of $162.5M (with free cash flow of $1.3B) against NVIDIA’s FY2026 surge to ~$215.9B revenue (+65.5% YoY), net income of $120.1B and a 55.6% net margin (free cash flow of $96.7B). It highlights NVIDIA’s lower valuation (Forward P/E 22.8x vs CrowdStrike 165.5x; P/S 23.0 vs 43.1) and very low leverage (debt-to-equity 0.1x vs 0.2x), while warning CrowdStrike’s reputational/legal risks following a 2024 incident could weigh on renewals. Overall, it argues NVIDIA is the better 2026 buy due to stronger profitability/cash generation and more attractive multiples.
The setup is less “best software vs best chips” and more a spread between self-funding growth and sentiment-repair growth. NVDA still has the cleaner earnings-power profile, but the market is increasingly paying for an assumption that AI capex stays linear; that makes it sensitive to any hyperscaler budget digestion or commentary about ROI normalization over the next 1-3 quarters. CRWD, by contrast, is still in a post-event trust rebuild, so the main variable is not product quality but renewal friction and sales efficiency; that tends to cap multiple expansion even if execution improves.
Second-order, NVDA’s moat is strong but not unassailable: TSM remains the key toll booth, while AMD and custom ASIC programs from large cloud buyers are the longer-dated margin pressure. The concentration of demand in a few large accounts is a bigger risk than the headline gross margin suggests, because any pause in one buyer’s capex can hit both revenue and the narrative simultaneously. For CRWD, the competitive spillover is toward platform vendors with broader suites (PANW, MSFT, ZS), since security teams often prefer fewer vendors after a high-profile disruption; that can slow standalone point-solution share gains for months, not days.
Contrarian view: the consensus is probably underpricing how much of NVDA’s upside is already a function of flawless execution and uninterrupted AI spending, while overestimating how quickly CRWD can regain premium valuation without cleaner evidence on renewals and SBC dilution. The more interesting setup is relative value, not outright longs: NVDA can outperform on fundamentals, but the upside from here likely depends on continued upward estimate revisions, not just “good” numbers. Falsifiers are straightforward: a capex air-pocket or export-control headline for NVDA, or any measurable deterioration in CRWD renewal trends / margin recovery over the next two quarters.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment